Advanced Enzyme Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 6, 2026, 2:03 am

Market Cap	3,310 Cr.
Current Price	295
Intrinsic Value	₹249.28
High / Low	367/259
Stock P/E	23.0
Book Value	133
Dividend Yield	1.76 %
ROCE	13.1 %
ROE	9.54 %
Face Value	2.00
PEG Ratio	4.67

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Advanced Enzyme Technologies Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Advanced Enzyme Technologies Ltd	3,310 Cr.	295	367/259	23.0	133	1.76 %	13.1 %	9.54 %	2.00
Aarti Drugs Limited	3,301 Cr.	361	575/312	17.8	147	0.55 %	13.5 %	13.0 %	10.0
Gujarat Themis Biosyn Ltd	3,226 Cr.	296	479/222	67.5	24.3	0.23 %	27.3 %	21.7 %	1.00
Suven Life Sciences Ltd	3,168 Cr.	137	303/113		12.4	0.00 %	87.0 %	87.2 %	1.00
RPG Life Sciences Ltd	3,103 Cr.	1,876	2,725/1,764	29.5	335	1.07 %	32.8 %	25.5 %	8.00
Industry Average	20,550.65 Cr	1,093.67		55.34	201.81	0.38%	16.35%	15.16%	6.10

All Competitor Stocks of Advanced Enzyme Technologies Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	142	139	147	158	161	158	155	146	169	167	186	185	172
Expenses	100	95	103	107	107	102	103	104	114	122	129	124	123
Operating Profit	42	44	44	51	54	55	51	42	55	46	56	60	49
OPM %	29%	32%	30%	32%	33%	35%	33%	29%	33%	27%	30%	33%	29%
Other Income	9	7	7	6	14	-6	7	10	8	9	9	10	20
Interest	1	1	1	1	1	1	1	1	1	1	1	1	1
Depreciation	9	8	9	9	9	9	9	9	9	10	10	10	10
Profit before tax	40	42	41	48	59	40	49	42	53	43	55	60	58
Tax %	31%	24%	29%	27%	28%	25%	28%	21%	27%	38%	26%	25%	26%
Net Profit	28	32	29	35	42	30	35	33	39	27	40	45	43
EPS in Rs	2.63	2.87	2.58	3.08	3.74	2.53	3.05	2.94	3.37	2.37	3.57	3.87	3.80

Last Updated: February 6, 2026, 8:47 pm

Below is a detailed analysis of the quarterly data for Advanced Enzyme Technologies Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

For Sales, as of Dec 2025, the value is 172.00 Cr.. The value appears to be declining and may need further review. It has decreased from 185.00 Cr. (Sep 2025) to 172.00 Cr., marking a decrease of 13.00 Cr..
For Expenses, as of Dec 2025, the value is 123.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 124.00 Cr. (Sep 2025) to 123.00 Cr., marking a decrease of 1.00 Cr..
For Operating Profit, as of Dec 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Sep 2025) to 49.00 Cr., marking a decrease of 11.00 Cr..
For OPM %, as of Dec 2025, the value is 29.00%. The value appears to be declining and may need further review. It has decreased from 33.00% (Sep 2025) to 29.00%, marking a decrease of 4.00%.
For Other Income, as of Dec 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Sep 2025) to 20.00 Cr., marking an increase of 10.00 Cr..
For Interest, as of Dec 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 1.00 Cr..
For Depreciation, as of Dec 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 10.00 Cr..
For Profit before tax, as of Dec 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Sep 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
For Tax %, as of Dec 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Sep 2025) to 26.00%, marking an increase of 1.00%.
For Net Profit, as of Dec 2025, the value is 43.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Sep 2025) to 43.00 Cr., marking a decrease of 2.00 Cr..
For EPS in Rs, as of Dec 2025, the value is 3.80. The value appears to be declining and may need further review. It has decreased from 3.87 (Sep 2025) to 3.80, marking a decrease of 0.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 2:16 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	239	222	293	329	391	420	444	502	529	541	624	637	710
Expenses	189	131	155	177	226	236	241	269	327	382	418	441	498
Operating Profit	50	91	138	152	165	184	203	232	203	158	206	196	211
OPM %	21%	41%	47%	46%	42%	44%	46%	46%	38%	29%	33%	31%	30%
Other Income	1	1	-3	3	1	5	6	9	6	21	21	33	48
Interest	13	9	8	4	9	5	4	3	3	3	4	5	3
Depreciation	10	9	9	13	18	21	26	28	35	35	35	37	40
Profit before tax	28	74	118	137	139	162	179	210	171	140	188	187	216
Tax %	23%	31%	35%	32%	33%	28%	26%	28%	28%	26%	27%	28%
Net Profit	21	51	77	93	94	116	133	151	124	104	137	134	155
EPS in Rs	1.85	4.60	6.97	8.20	8.07	9.95	11.58	13.09	10.70	9.45	11.92	11.72	13.61
Dividend Payout %	6%	4%	3%	5%	6%	6%	5%	7%	9%	11%	43%	44%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	142.86%	50.98%	20.78%	1.08%	23.40%	14.66%	13.53%	-17.88%	-16.13%	31.73%	-2.19%
Change in YoY Net Profit Growth (%)	0.00%	-91.88%	-30.20%	-19.70%	22.33%	-8.75%	-1.12%	-31.41%	1.75%	47.86%	-33.92%

Advanced Enzyme Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	11%
5 Years:	7%
3 Years:	6%
TTM:	6%

Compounded Profit Growth
10 Years:	10%
5 Years:	0%
3 Years:	3%
TTM:	-8%

Stock Price CAGR
10 Years:	%
5 Years:	8%
3 Years:	8%
1 Year:	-25%

Return on Equity
10 Years:	14%
5 Years:	11%
3 Years:	10%
Last Year:	10%

Last Updated: September 4, 2025, 10:20 pm

Balance Sheet

Last Updated: December 4, 2025, 12:54 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	22	22	22	22	22	22	22	22	22	22	22	22	22
Reserves	145	188	256	442	537	657	817	949	1,066	1,213	1,302	1,398	1,462
Borrowings	167	115	101	54	67	35	28	28	35	34	47	39	35
Other Liabilities	73	92	71	65	102	91	104	150	137	142	150	151	173
Total Liabilities	406	417	450	583	727	805	971	1,149	1,260	1,411	1,521	1,611	1,692
Fixed Assets	287	287	285	421	491	495	563	604	619	649	650	679	683
CWIP	2	5	7	8	11	10	10	10	15	22	41	22	31
Investments	0	0	0	0	0	111	124	121	102	360	403	480	529
Other Assets	117	125	158	153	226	188	275	414	524	380	427	430	449
Total Assets	406	417	450	583	727	805	971	1,149	1,260	1,411	1,521	1,611	1,692

Below is a detailed analysis of the balance sheet data for Advanced Enzyme Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
For Reserves, as of Sep 2025, the value is 1,462.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,398.00 Cr. (Mar 2025) to 1,462.00 Cr., marking an increase of 64.00 Cr..
For Borrowings, as of Sep 2025, the value is 35.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 4.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 173.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 151.00 Cr. (Mar 2025) to 173.00 Cr., marking an increase of 22.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 1,692.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,611.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 81.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 683.00 Cr.. The value appears strong and on an upward trend. It has increased from 679.00 Cr. (Mar 2025) to 683.00 Cr., marking an increase of 4.00 Cr..
For CWIP, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 9.00 Cr..
For Investments, as of Sep 2025, the value is 529.00 Cr.. The value appears strong and on an upward trend. It has increased from 480.00 Cr. (Mar 2025) to 529.00 Cr., marking an increase of 49.00 Cr..
For Other Assets, as of Sep 2025, the value is 449.00 Cr.. The value appears strong and on an upward trend. It has increased from 430.00 Cr. (Mar 2025) to 449.00 Cr., marking an increase of 19.00 Cr..
For Total Assets, as of Sep 2025, the value is 1,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,611.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 81.00 Cr..

Notably, the Reserves (1,462.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	43	54	93	107	116	129	141	163	122	140	141	142
Cash from Investing Activity +	-25	-15	-10	-60	-60	-124	-43	-27	2	-286	-65	-89
Cash from Financing Activity +	-20	-36	-63	-65	-2	-43	-39	-26	-48	-26	-59	-73
Net Cash Flow	-1	2	21	-18	54	-38	60	109	75	-171	17	-20

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-117.00	-24.00	37.00	98.00	98.00	149.00	175.00	204.00	168.00	124.00	159.00	157.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	49	61	52	55	55	51	61	63	61	68	58	66
Inventory Days	387	403	358	352	339	363	361	346	402	343	375	378
Days Payable	81	89	68	57	78	46	43	56	60	67	40	41
Cash Conversion Cycle	356	374	342	351	315	369	379	353	404	344	393	403
Working Capital Days	-54	-43	3	76	47	72	90	94	116	109	102	112
ROCE %	12%	25%	36%	31%	25%	24%	22%	22%	15%	12%	15%	13%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	49.88%	46.52%	45.92%	43.62%	43.50%	43.02%	42.95%	42.92%	43.08%	43.08%	43.08%	43.04%
FIIs	21.86%	21.89%	22.27%	22.54%	23.01%	12.03%	12.63%	12.57%	11.90%	23.45%	25.41%	25.85%
DIIs	5.73%	7.58%	6.49%	6.98%	7.56%	8.08%	8.02%	8.17%	8.19%	8.45%	6.41%	5.51%
Public	22.54%	24.02%	25.34%	26.88%	25.95%	36.87%	36.40%	36.31%	36.82%	25.00%	25.09%	25.62%
No. of Shareholders	77,537	75,052	72,642	73,034	68,640	65,222	66,758	67,351	65,322	67,589	69,637	68,051

Shareholding Pattern Chart

No. of Shareholders

Advanced Enzyme Technologies Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
UTI MNC Fund	1,037,821	1.12	30.8	N/A	N/A	N/A
ICICI Prudential ESG Exclusionary Strategy Fund	872,022	1.82	25.88	N/A	N/A	N/A
Bank of India ELSS Tax Saver	38,876	0.08	1.15	118,151	2026-02-21 03:10:27	-67.1%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	11.72	11.92	9.45	10.70	13.09
Diluted EPS (Rs.)	11.71	11.92	9.45	10.68	13.07
Cash EPS (Rs.)	15.24	15.40	12.42	14.20	16.10
Book Value[Excl.RevalReserv]/Share (Rs.)	127.00	122.61	114.84	102.00	92.25
Book Value[Incl.RevalReserv]/Share (Rs.)	127.00	122.61	114.84	102.00	92.25
Revenue From Operations / Share (Rs.)	56.93	55.79	48.35	47.35	44.92
PBDIT / Share (Rs.)	20.33	21.56	16.27	18.59	21.51
PBIT / Share (Rs.)	17.06	18.41	13.13	15.46	18.97
PBT / Share (Rs.)	16.75	16.80	12.55	15.30	18.83
Net Profit / Share (Rs.)	11.97	12.25	9.29	11.07	13.56
NP After MI And SOA / Share (Rs.)	11.72	11.92	9.45	10.70	13.08
PBDIT Margin (%)	35.71	38.64	33.64	39.26	47.89
PBIT Margin (%)	29.97	33.00	27.16	32.65	42.23
PBT Margin (%)	29.41	30.10	25.96	32.31	41.91
Net Profit Margin (%)	21.03	21.95	19.21	23.38	30.18
NP After MI And SOA Margin (%)	20.58	21.36	19.53	22.58	29.13
Return on Networth / Equity (%)	9.22	10.06	8.55	10.98	15.06
Return on Capital Employeed (%)	12.52	14.40	10.92	14.31	19.53
Return On Assets (%)	8.08	8.68	7.42	9.43	12.68
Long Term Debt / Equity (X)	0.01	0.01	0.01	0.01	0.01
Total Debt / Equity (X)	0.01	0.01	0.01	0.01	0.01
Asset Turnover Ratio (%)	0.40	0.42	0.33	0.32	0.38
Current Ratio (X)	9.09	7.61	9.31	10.00	7.64
Quick Ratio (X)	7.47	6.22	7.71	8.00	6.25
Inventory Turnover Ratio (X)	4.17	1.14	1.23	1.30	1.32
Dividend Payout Ratio (NP) (%)	43.49	41.94	10.58	8.41	4.58
Dividend Payout Ratio (CP) (%)	34.01	33.17	7.94	6.50	3.83
Earning Retention Ratio (%)	56.51	58.06	89.42	91.59	95.42
Cash Earning Retention Ratio (%)	65.99	66.83	92.06	93.50	96.17
Interest Coverage Ratio (X)	63.95	82.35	75.13	115.72	150.80
Interest Coverage Ratio (Post Tax) (X)	38.66	52.94	45.58	69.93	96.02
Enterprise Value (Cr.)	3081.99	3814.49	2529.42	2942.98	3729.91
EV / Net Operating Revenue (X)	4.84	6.11	4.68	5.56	7.43
EV / EBITDA (X)	13.55	15.82	13.91	14.16	15.52
MarketCap / Net Operating Revenue (X)	4.90	6.23	4.79	5.96	7.68
Retention Ratios (%)	56.50	58.05	89.41	91.58	95.41
Price / BV (X)	2.20	2.93	2.10	2.90	3.97
Price / Net Operating Revenue (X)	4.90	6.23	4.79	5.96	7.68
EarningsYield	0.04	0.03	0.04	0.03	0.03

After reviewing the key financial ratios for Advanced Enzyme Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.72, marking a decrease of 0.20.
For Diluted EPS (Rs.), as of Mar 25, the value is 11.71. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.71, marking a decrease of 0.21.
For Cash EPS (Rs.), as of Mar 25, the value is 15.24. This value is within the healthy range. It has decreased from 15.40 (Mar 24) to 15.24, marking a decrease of 0.16.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.00. It has increased from 122.61 (Mar 24) to 127.00, marking an increase of 4.39.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.00. It has increased from 122.61 (Mar 24) to 127.00, marking an increase of 4.39.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 56.93. It has increased from 55.79 (Mar 24) to 56.93, marking an increase of 1.14.
For PBDIT / Share (Rs.), as of Mar 25, the value is 20.33. This value is within the healthy range. It has decreased from 21.56 (Mar 24) to 20.33, marking a decrease of 1.23.
For PBIT / Share (Rs.), as of Mar 25, the value is 17.06. This value is within the healthy range. It has decreased from 18.41 (Mar 24) to 17.06, marking a decrease of 1.35.
For PBT / Share (Rs.), as of Mar 25, the value is 16.75. This value is within the healthy range. It has decreased from 16.80 (Mar 24) to 16.75, marking a decrease of 0.05.
For Net Profit / Share (Rs.), as of Mar 25, the value is 11.97. This value is within the healthy range. It has decreased from 12.25 (Mar 24) to 11.97, marking a decrease of 0.28.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.72, marking a decrease of 0.20.
For PBDIT Margin (%), as of Mar 25, the value is 35.71. This value is within the healthy range. It has decreased from 38.64 (Mar 24) to 35.71, marking a decrease of 2.93.
For PBIT Margin (%), as of Mar 25, the value is 29.97. This value exceeds the healthy maximum of 20. It has decreased from 33.00 (Mar 24) to 29.97, marking a decrease of 3.03.
For PBT Margin (%), as of Mar 25, the value is 29.41. This value is within the healthy range. It has decreased from 30.10 (Mar 24) to 29.41, marking a decrease of 0.69.
For Net Profit Margin (%), as of Mar 25, the value is 21.03. This value exceeds the healthy maximum of 10. It has decreased from 21.95 (Mar 24) to 21.03, marking a decrease of 0.92.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.58. This value exceeds the healthy maximum of 20. It has decreased from 21.36 (Mar 24) to 20.58, marking a decrease of 0.78.
For Return on Networth / Equity (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 15. It has decreased from 10.06 (Mar 24) to 9.22, marking a decrease of 0.84.
For Return on Capital Employeed (%), as of Mar 25, the value is 12.52. This value is within the healthy range. It has decreased from 14.40 (Mar 24) to 12.52, marking a decrease of 1.88.
For Return On Assets (%), as of Mar 25, the value is 8.08. This value is within the healthy range. It has decreased from 8.68 (Mar 24) to 8.08, marking a decrease of 0.60.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.42 (Mar 24) to 0.40, marking a decrease of 0.02.
For Current Ratio (X), as of Mar 25, the value is 9.09. This value exceeds the healthy maximum of 3. It has increased from 7.61 (Mar 24) to 9.09, marking an increase of 1.48.
For Quick Ratio (X), as of Mar 25, the value is 7.47. This value exceeds the healthy maximum of 2. It has increased from 6.22 (Mar 24) to 7.47, marking an increase of 1.25.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.17. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 4.17, marking an increase of 3.03.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 43.49. This value is within the healthy range. It has increased from 41.94 (Mar 24) to 43.49, marking an increase of 1.55.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 34.01. This value is within the healthy range. It has increased from 33.17 (Mar 24) to 34.01, marking an increase of 0.84.
For Earning Retention Ratio (%), as of Mar 25, the value is 56.51. This value is within the healthy range. It has decreased from 58.06 (Mar 24) to 56.51, marking a decrease of 1.55.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 65.99. This value is within the healthy range. It has decreased from 66.83 (Mar 24) to 65.99, marking a decrease of 0.84.
For Interest Coverage Ratio (X), as of Mar 25, the value is 63.95. This value is within the healthy range. It has decreased from 82.35 (Mar 24) to 63.95, marking a decrease of 18.40.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.66. This value is within the healthy range. It has decreased from 52.94 (Mar 24) to 38.66, marking a decrease of 14.28.
For Enterprise Value (Cr.), as of Mar 25, the value is 3,081.99. It has decreased from 3,814.49 (Mar 24) to 3,081.99, marking a decrease of 732.50.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.84. This value exceeds the healthy maximum of 3. It has decreased from 6.11 (Mar 24) to 4.84, marking a decrease of 1.27.
For EV / EBITDA (X), as of Mar 25, the value is 13.55. This value is within the healthy range. It has decreased from 15.82 (Mar 24) to 13.55, marking a decrease of 2.27.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.90. This value exceeds the healthy maximum of 3. It has decreased from 6.23 (Mar 24) to 4.90, marking a decrease of 1.33.
For Retention Ratios (%), as of Mar 25, the value is 56.50. This value is within the healthy range. It has decreased from 58.05 (Mar 24) to 56.50, marking a decrease of 1.55.
For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has decreased from 2.93 (Mar 24) to 2.20, marking a decrease of 0.73.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.90. This value exceeds the healthy maximum of 3. It has decreased from 6.23 (Mar 24) to 4.90, marking a decrease of 1.33.
For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Advanced Enzyme Technologies Ltd as of March 6, 2026 is: ₹237.57

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 6, 2026, Advanced Enzyme Technologies Ltd is Overvalued by 19.47% compared to the current share price ₹295.00

Intrinsic Value of Advanced Enzyme Technologies Ltd as of March 6, 2026 is: ₹249.28

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 6, 2026, Advanced Enzyme Technologies Ltd is Overvalued by 15.50% compared to the current share price ₹295.00

Last 5 Year EPS CAGR: 4.93%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 21.00%, which is a positive sign. The company has higher reserves (802.46 cr) compared to borrowings (60.38 cr), indicating strong financial stability. The company has shown consistent growth in sales (452.38 cr) and profit (149.92 cr) over the years.	The stock has a high average Working Capital Days of 60.33, which may not be favorable. The stock has a high average Cash Conversion Cycle of 365.25, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Advanced Enzyme Technologies Ltd:
1. Net Profit Margin: 21.03%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 12.52% (Industry Average ROCE: 16.35%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 9.22% (Industry Average ROE: 15.16%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 38.66
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 7.47
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 23 (Industry average Stock P/E: 55.34)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Advanced Enzyme Technologies Ltd. is a Public Limited Listed company incorporated on 15/03/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24200MH1989PLC051018 and registration number is 051018. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 351.41 Cr. and Equity Capital is Rs. 22.38 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	A - Wing, Sun Magnetica, 5th Floor, LIC Service Road, Thane Maharashtra 400604	Contact not found

Management
Name	Position Held
Mr. Vasant Rathi	Non Executive Chairman
Mr. Mukund Kabra	Whole Time Director
Ms. Rasika Rathi	Non Executive Director
Dr. Sunny Sharma	Non Executive Director
Mr. Pramod Kasat	Independent Director
Mrs. Vandana Tilak	Independent Director
Ms. Rajshree Patel	Independent Director
Mr. Nitin Desmukh	Independent Director
Mr. Vinodkumar Jajoo	Independent Director

FAQ

What is the intrinsic value of Advanced Enzyme Technologies Ltd?

Advanced Enzyme Technologies Ltd's intrinsic value (as of 06 March 2026) is ₹249.28 which is 15.50% lower the current market price of ₹295.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,310 Cr. market cap, FY2025-2026 high/low of ₹367/259, reserves of ₹1,462 Cr, and liabilities of ₹1,692 Cr.

What is the Market Cap of Advanced Enzyme Technologies Ltd?

The Market Cap of Advanced Enzyme Technologies Ltd is 3,310 Cr..

What is the current Stock Price of Advanced Enzyme Technologies Ltd as on 06 March 2026?

The current stock price of Advanced Enzyme Technologies Ltd as on 06 March 2026 is ₹295.

What is the High / Low of Advanced Enzyme Technologies Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Advanced Enzyme Technologies Ltd stocks is ₹367/259.

What is the Stock P/E of Advanced Enzyme Technologies Ltd?

The Stock P/E of Advanced Enzyme Technologies Ltd is 23.0.

What is the Book Value of Advanced Enzyme Technologies Ltd?

The Book Value of Advanced Enzyme Technologies Ltd is 133.

What is the Dividend Yield of Advanced Enzyme Technologies Ltd?

The Dividend Yield of Advanced Enzyme Technologies Ltd is 1.76 %.

What is the ROCE of Advanced Enzyme Technologies Ltd?

The ROCE of Advanced Enzyme Technologies Ltd is 13.1 %.

What is the ROE of Advanced Enzyme Technologies Ltd?

The ROE of Advanced Enzyme Technologies Ltd is 9.54 %.

What is the Face Value of Advanced Enzyme Technologies Ltd?

The Face Value of Advanced Enzyme Technologies Ltd is 2.00.